Why the study?
Do group III antiarrhythmic drugs (bepridil, amiodarone, sotalol) improve sinus rhythm maintenance in patients with persistent atrial fibrillation?
Do group III antiarrhythmic drugs (bepridil, amiodarone, sotalol) improve sinus rhythm maintenance in patients with persistent atrial fibrillation?
Bepridil is highly effective for rhythm control in persistent atrial fibrillation but requires strict monitoring for QT prolongation, torsade de pointes, and interstitial pneumonia.
Answers are grounded in this paper and cite their sources.
Bepridil may support rhythm control in persistent AF with rigorous QT monitoring; leaves open randomized confirmation of superiority and safety versus amiodarone.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Yuji Nakazato (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: